A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 11 Dec 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Apalutamide (Primary) ; Gonadotropin releasing hormone
Indications Adenocarcinoma; Prostate cancer
Focus Registrational; Therapeutic Use
Acronyms TITAN
Sponsors Aragon Pharmaceuticals; Janssen Research & Development; Janssen-Cilag

21 Oct 2024 Planned End Date changed from 1 Sep 2025 to 31 Dec 2027.
25 Jul 2024 Planned End Date changed from 5 Sep 2024 to 1 Sep 2025.
27 Jan 2024 Results assessing the OS medians for APA and PBO arms beyond the TITAN follow-up, presented at the 2024 Genitourinary Cancers Symposium

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com